期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PAD方案成功治疗难治性套细胞淋巴瘤一例报告 被引量：5

原文传递
导出
摘要 1病例报告 患者女，58岁，2009—01无明显诱因出现胸闷，伴有夜间阵发性干咳，无发热、盗汗、体质量减轻等。2009—03，上述症状加重，当地医院B超检查提示脾大；胸片检查提示双侧胸腔积液（中量）。抗感染、抽胸腔积液等对症治疗无效，2009—04—03来我院，住院后检查B超：双侧颈部、腋窝、腹股沟及腹膜后多发肿大淋巴结。
作者 梁蓉 陈协群 白庆咸 顾宏涛 高广勋 董红娟 朱华锋 吴静
机构地区 第四军医大学附属西京医院血液科
出处 《中华肿瘤防治杂志》 CAS 2011年第12期968-969,共2页 Chinese Journal of Cancer Prevention and Treatment
关键词 淋巴瘤 硼替佐米 病例报告
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Banks P M, Chan J, Cleary M L, et al. Mantle cell lymphoma:A proposal for unification of morphologic, immunologic and mo leculardata[J]. AmJ SurgPathol, 1992, 16(7) :637-640.
  • 2Wei A H, Roberts A W. Bortezomib: putting mantle cell lym phoma on death row[J]. Leuk Lymphoma,2008,49(4):657- 658.
  • 3Suh N S, Goy A. Bortezomib in mantle cell lymphoma[J]. Fu- ture Oncol, 2008, 4(2): 149-168.
  • 4Jares P, Colomer D, Canmpo E. Genetic and molecular patho- genesis of mantle cell lymphoma: Perspectives for new targeted therapeutics[J].Nat RevCancer, 2007,7(1) :750-754.
  • 5Ghielmini M, Zucca E. How I treat mantle cell lymphoma[J].Blood,2009, 114(8) :1469-1476.
  • 6Belaud-Rotureau M A, Parrens M, Dubus P, et al. A compara tive analysis of FISH, RT-PCR, PCR, and immunohistochemis try for the diagnosis of mantle cell lymphomas[J].Mod Pathol, 2002,15 (5) : 517-525.
  • 7Schmidt C, Dreyling M. Therapy of mantle cell lymphoma: cur rent standards and future strategies[J].Hematol Oncol Clin North Am, 2008, 22(5):953-963.
  • 8Kasamon Y L. Blood or marrow transplantation for mantle cell lymphoma[J]. Curr Opin Oncol, 2007, 19 (2) :128-135.
  • 9Wang M, Han X H, Zhang L, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo[J].Leukemia, 2008, 22(1) :179-185.
  • 10Goy A, Bernstein S H, Kahl B S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time- to event analyses of the multicenter phase 2 PINNACLE study [J]. AnnOncol, 2009, 20(3):520-525.

二级参考文献14

  • 1Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 2003, 348 : 2609-2617.
  • 2Richardson P, Jaomath S, Colson K. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Clin Adv Hematol Oncol, 2006, 4:1-8.
  • 3Hideshinm T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimeloma activity of proteasome inhibitor PS- 341. Blood, 2003, 101 : 1530-1534.
  • 4Oakervee HE, Popat R, Curry N, et al. PAD combination therapy ( PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol, 2005, 129:755-762.
  • 5Richardson P, Mitsiades C, Schlossman R, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program, 2007: 317-323.
  • 6Durie BG , Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia, 2006, 20:1467-1473.
  • 7Greipp PR, San Miguel J, Durie BG, et al. International staging system for muhiple myeloma. J Clin Oncol, 2005, 23:3412- 3420.
  • 8Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in muhiple myeloma cells. Blood, 2006, 107: 4907-4916.
  • 9Gu H, Chen X, Gao G, et al. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther, 2008, 7: 2298-2307.
  • 10Meister S, Schubert U, Neubert K, et al. Extensive immuno- globulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res, 2007, 67: 1783-1792.

共引文献9

同被引文献80

  • 1Glimcher LH. XBP1 : the last two decades[-J. Ann Rheum Dis, 2010,69(Suppl 1):67 71.
  • 2Koong AC,Chauhan V,Romero Ramirez L. Targeting XBP-1 as a novel anti cancer strategyJ. Cancer Biol 8,- Ther, 2006,5 (7) :756-759.
  • 3Hetz C, Martinon F, Rodriguez D, et al. The unfolded protein re sponseintegrating stress signals through the stress sensor IRElaJ. Physiol Rev,2011,91(4):1219-1243.
  • 4Glimcher LH, Lee AH. From sugar to fat how the transcription factor XBP1 regulates hepatic lipogenesisJ. Ann N Y Acad Sci,2009,1173 Suppl l:E2-E9.
  • 5Van Schadewiik A,Van't Wout EF,Stolk J,et al. A quantitative method for detection of spliced X box binding protein-1 (XBP1) mRNA as a measure of endoplasmic reticulum (ER)stress. Cell Stress Chaperones,2012,17(2) =275-279.
  • 6MinvilleWalz M, Pierre AS, Pichon L, et al. Inhibition of stearoyl- CoA desaturase 1 expression induces CHOP-dependent cell death in human cancer cells. Plo, 2010,5 (12) = e14363.
  • 7Run D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol, 2007,8 (7) :519-529.
  • 8Lee AH,Iwakoshi NN,Glimcher LH. XBP-1 regulates a subset of en- doplasmic reticulum resident chaperone genes in the unfolded protein reslmnse. Molecular Cdlular, 2003,23 ( 21) = 7448-7459.
  • 9Shaffer AL,Shapiro-Shelef M,Iwakoshi NN',et al. XBP1 ,down- stream of Bbmp-1, expands the secretory apparatus and other or- ganelles,and increases protein synthesis in plasma cell differenti- ation 1- Immunity, 2004,21 ( 1 ) : 81-93.
  • 10Sriburi R, Bommiasamy H,Buldak GL, et al. Coordinate regula tion of phospholipid biosynthesis and secretory pathway gene ex- pression in XBP 1 (S)-induced endoplasmic reticulum biogenesis[J]. J BiolChem,2007,282(10):7024-7034.

引证文献5

二级引证文献18

中华肿瘤防治杂志
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部